Representative HES, p16 and HPV staining of biopsies from NR and CCR individuals.

<p>HES-NR and HES CCR correspond to hematoxylin-eosin-safran staining of representative non-responder and complete clinical responder individuals, respectively, and IHC-p16 and HIS-oncogenic HPV correspond to representative positive immunohistochemistry for the p16 antigen (brown staining) and hybridization <i>in situ</i> for oncogenic HPV DNA (blue punctate nuclear staining), respectively. The bar represents 40 microns in the upper panels and 20 microns in the lower panels.</p

Patient Characteristics.

<p>Abbreviations: *Age at diagnosis; ⁺Response to induction therapy, CCR, complete clinical responder; NR, non-responder; <b>^†</b> Alive (A) or Deceased (D) in 2009 ; MA, microarray; TLDA, Taqman low density array card; PF, Cisplatin/5FU; T1PF, Cisplatin/5FU/Paclitaxel; T2PF, Cisplatin/5FU /Docetaxel.</p

Gene Signature That Predicts Response to PF.

<p>Gene Signature That Predicts Response to PF.</p

Multidimensional scaling in three dimensions (using Euclidean distances) of the microarray (MA) and TLDA (TLDA) gene expression data.

<p>The 10-gene classifier clearly separates the members of the NR (blue spheres) and CCR (red spheres) groups. 82–83 per cent of the variability is contained in these first three dimensions.</p

Statistical Summary for 10 Gene Predictor.

*<p>The samples in this group contained all but one of the samples analyzed by MA. **Samples in this group contained the 5 additional samples analyzed by TLDA that were not analyzed by MA.</p

Characteristics of Patients (Microarray Study).

*<p>The probability was calculated with the Fisher Exact Test.</p>**<p>Alcohol was consumed predominantly in the form of red wine.</p><p>Note that the HPV status could not be ascertained for one individual of the Responder group.</p

Characteristics of Patients (TLDA Study).

<p>Characteristics of Patients (TLDA Study).</p